T ranscatheter aortic valve replacement (TAVR) was initially developed as a method by which patients with prohibitive surgical risk could undergo aortic valve replacement. 1, 2 Through further technological and clinical refinement, this procedure has become a viable option for patients at intermediate or high surgical risk as well. [3] [4] [5] The primary advantage of TAVR has always been its less invasive nature in comparison with surgical aortic valve replacement. To this end, many of the advances in TAVR have revolved around minimizing the invasive nature of all aspects of the aortic valve replacement, including anesthesia.
A number of recent reports have described singlecenter experiences using local anesthesia with conscious sedation during TAVR, forgoing the general anesthesia that was used almost exclusively in the initial large randomized studies of high-and extreme-risk patients. [2] [3] [4] 6, 7 It is important to note that these conscious sedation studies have shown feasibility without sacrificing procedural success or demonstrating evidence of harm. Also, these studies report that use of conscious sedation leads to a reduction in operation room times, length of intensive care unit (ICU) admissions, overall patient length of stay, and costs. 6 To better address whether conscious sedation may be used safely in a broader clinical setting, a larger population is needed to perform a true comparative effectiveness analysis. To this end, we characterized the patients who received elective percutaneous transfemoral TAVR in the United States through use of the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, a mandatory reporting registry for all US cases. We then compared outcomes of patients among those who underwent TAVR with conscious sedation against those who underwent TAVR with general anesthesia.
METHODS

Society of Thoracic Surgeons/American College of Cardiology TVT Registry
The Society of Thoracic Surgery/American College of Cardiology TVT Registry is a national registry with participation mandated for all US TAVR implanters by the Centers for Medicare & Medicaid Services National Coverage Determinations. 7 The registry collects information on demographics, comorbidities, periprocedural details, and inhospital and 30-day clinical outcomes. All consecutive adults (age >18 years) in the United States who underwent percutaneous, elective, or urgent transfemoral TAVR between April 2014 and June 2015 were included in the analysis (Figure 1 ). Procedures that used a femoral cutdown, minithoracotomy, or ministernotomy, procedures categorized as emergent or salvage, valve-in-valve procedures, patients who underwent a concurrent procedure, and patients enrolled in a research study were excluded from this analysis. A TVT Registry protocol was submitted to Chesapeake Research Review Inc., the designated institutional review board for this registry, which approved the study and granted a waiver of informed consent.
General and Conscious Sedation
Anesthesia type is a category within the standard periprocedural data acquired for the Society of Thoracic Surgeons/ American College of Cardiology TVT Registry data collection form. The coder dictionary defines general anesthesia as "a drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation." Conscious sedation/analgesia is defined as "a drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation." Patients who were converted from conscious sedation to general anesthesia were labeled with an option termed combination in the data collection form. As such, analyses of the conscious sedation group include the patient populations identified as both conscious sedation and combination in an effort to capture the outcomes of all patients undergoing conscious sedation on an intention-totreat basis.
Outcomes
The primary outcome assessed was in-hospital mortality. Secondary in-hospital outcomes included procedural success, ICU length of stay, hospital length of stay, mortality, a composite end point of mortality and stroke, and discharge rates to home. Secondary 30-day outcomes included mortality and a composite end point of mortality and stroke that were available for 85% of the cohort. Post hoc falsification end point analyses were performed to evaluate for the presence of
Clinical Perspective
What Is New?
• From April 1, 2014, to June 30, 2015, conscious sedation was used with increasing frequency for transcatheter aortic valve replacement in the United States.
• Conscious sedation was associated with briefer length of stay and lower in-hospital and 30-day mortality than general anesthesia in patients undergoing percutaneous, transfemoral transcatheter aortic valve replacement.
What Are the Clinical Implications?
• Conscious sedation is growing in popularity as an anesthetic choice for transcatheter aortic valve replacement, although most patients continue to be treated with general anesthesia.
• Conscious sedation should be considered in patients undergoing elective, percutaneous transfemoral transcatheter aortic valve replacement after careful evaluation of individualized risks and benefits by the heart team.
possible unmeasured confounding among the adjusted analyses. Assessed falsification end points included in-hospital access site complications (major plus minor), access site bleeding, and the need for a new permanent pacemaker or implantable cardiac defibrillator. All outcomes were reported by the site to the registry by using standardized definitions and harmonized with Valve Academic Research Consortium definitions.
8,9
Statistical Analysis
A propensity score analysis using inverse probability of treatment weighting was used to control for potential differences in the type of patient selected for conscious sedation versus general anesthesia. The propensity analysis was nonparsimonious by using 51 variables. All variables in the internally validated in-hospital TVT Registry mortality model were used: age at randomization, sex, body mass index, left ventricular ejection fraction, hemoglobin, platelet count, estimated glomerular filtration rate, number of days between the procedural date and November 1, 2011, race, hemodialysis, left main stenosis >50%, proximal left anterior descending coronary artery disease >70%, prior myocardial infarction, endocarditis, prior stroke or transient ischemic attack, peripheral arterial disease, current/recent smoker, diabetes mellitus, New York Heart Association class IV, atrial fibrillation/atrial/ flutter, conduction defect, severe chronic lung disease, home oxygen use, hostile chest, porcelain aorta, femoral access site, pacemaker, previous implantable-cardioverter defibrillator, prior percutaneous coronary intervention, prior coronary artery bypass graft, prior cardiac surgery, prior aortic valve procedure, prior nonaortic valve procedure, degenerative aortic valve, valve morphology, aortic insufficiency, mitral insufficiency, tricuspid insufficiency, procedural acuity, carotid stenosis, aortic valve area, creatinine, hypertension, stable angina, aortic annulus diameter, mean aortic gradient, right ventricular systolic pressure, valve type, and inoperable/extreme risk. 10 Covariance balance was assessed visually using the Cramer φ measure of association and R squared measurements. We then selected several additional covariates deemed relevant to this particular analysis: sheath size, total number of TAVR procedures performed for each site, chronic lung disease, and prior balloon aortic valvuloplasty. An additional sensitivity analysis was performed to assess frailty using the 5-meter walk test. Sites were requested to report if the patient was able to walk or not and report 3 test results. For the purposes of this analysis, patients reported as unable to walk were assigned the speed of the first percentile. Logistic regression models with generalized estimating equations and a random intercept were created to assess the association between sedation type and the discrete end points of interest adjusted for all factors used in the propensity score analysis and incorporating the inverse probability of treatment weighted weights. The generalized estimating equation selection is used to account for the expectation that patients from the same site are more likely to have similar responses relative to patients from other sites. Because there is a potential for sites to prefer one type of sedation over the other, the random intercept was incorporated into each model. The distributions of the secondary outcomes length of stay and procedure duration were skewed. To address this, Poisson models with robust variance estimation were performed. The relative risks from these models are reported. Before modeling continuous risk factors, the distribution of these measurements was assessed and modeling assumptions were verified. Continuous risk factors were assessed for potential outliers by examining the 1% and 99% quintiles of the univariate distributions. Because of significant amounts of missing data for right ventricular systolic pressure, carotid stenosis, and mitral regurgitation, 5 multiple imputation data sets using monotone missing pattern was performed for these covariates. No additional imputations were performed on the prespecified covariates (Table I in the online-only Data Supplement). Tests for statistical significance were generated using χ 2 tests for discrete factors and the t test for continuous factors. Figure 2A reports the Cochran-Armitage trend test. Analyses were performed with SAS version 9.2 or higher (SAS Institute, Inc).
RESULTS
Trends in Anesthesia Use Over Time
From April 1, 2014, to June 30, 2015, 10 997 patients underwent elective percutaneous transfemoral TAVR at 314 US hospitals. A total of 1737 (15.8%) were treated with conscious sedation. The percentage of national TAVR cases performed under conscious sedation rose from 11% per quarter to 20% per quarter over this time (P<0.001, Figure 2A) . Concordantly, the number of sites that used conscious sedation for at least 1 TAVR case rose as well ( Figure 2B ). Over the studied time period, there was mixed usage of both anesthetic techniques among sites that performed conscious sedation cases (Figure I and Table II in the online-only Data Supplement). Conversion from conscious sedation to general anesthesia was noted in 102 of 1737 (5.9%) of cases (Table III in 
Baseline Characteristics of the Study Population
The mean age of patients in the general anesthesia group was significantly greater than that in the conscious sedation group ( 
Unadjusted In-Hospital and 30-Day Outcomes
Intraprocedural success with conscious sedation and general anesthesia was similar (98.2% versus 98.5%, P=0.31). The conscious sedation group was less likely to experience in-hospital (1.6% versus 2.5%, P=0.03, 
Adjusted In-Hospital and 30-Day Outcomes
After using propensity analyses to adjust for multiple demographic and clinical factors ( Figure II in the online-only Data Supplement), TAVR with conscious sedation was associated with lower procedural success (97.9% versus 98.6%, P<0.001) and a reduced rate of mortality at the in-hospital (1.5% versus 2.4%, P=0.01) and 30-day (2.3% versus 4.0%, P<0.001) time points, and reduced rates of in-hospital and 30-day mortality/stroke (Table 2) in comparison with general anesthesia. The mortality difference between conscious sedation and general anesthesia persisted in a post hoc sensitivity analysis accounting for frailty as assessed by the 5-meter walk test (odds ratio, 0.58 [95% CI, 0.50-0.67]; P<0.001). Conscious sedation was associated with briefer ICU length of stay and hospital length of stay than general anesthesia. Patients undergoing TAVR with conscious sedation were more likely to be discharged to home than those receiving general anesthesia ( Table 2, Table IV in the online-only Data Supplement).
Falsification End Point Analysis
In unadjusted analyses, patients treated under general anesthesia were more likely to experience vascular complications than patients treated under conscious sedation. After adjustment, this relationship became nonsignificant. Access site bleeding was not statistically different in unadjusted or adjusted analyses between groups. In unadjusted analyses, patients treated under conscious sedation were more likely to require new pacemaker/implantable cardiac defibrillator implantation than patients treated under general anesthesia. After adjustment, this relationship became nonsignificant. All falsification end point results are reported in Table 3 .
DISCUSSION
The current study demonstrates that conscious sedation has become increasingly adopted across US TAVR centers. We sought to address the limited evidence base for this practice through use of the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology TVT Registry to evaluate the real-world impact of anesthetic choice on patient outcomes in current clinical practice. We discovered that percutaneous transfemoral TAVR with conscious sedation was associated with reduced mortality rates in comparison with TAVR with general anesthesia. Several other advantages were seen, including associations with reduced procedural inotrope use, shorter ICU and overall hospital length of stays, and reduction in combined rates of death/stroke. These findings have the potential to alter the current standard of care for TAVR.
Since the inception of TAVR, many innovations have occurred, both technological and procedural. These advances have often been synergistic: reduced delivery profiles and sheath sizes have allowed for the procedural progression from a midline sternotomy to a femoral artery cut down to a percutaneous needle stick. 11 As the physical and hemodynamic stresses of the procedure have lessened, the intensity of anesthetic support required has declined as well. Transitioning from general anesthesia to conscious sedation may allow TAVR cases to move from operating rooms to catheterization laboratories and improve postprocedural recovery times. Earlier time to ambulation and decreased length of hospitalization are associated with significant financial cost savings. 6, 12 The sample of US TAVR centers in this study demonstrates that the improvements in efficiency do not significantly compromise high rates of procedural success. Although the adjusted rates of procedural success in the conscious sedation arm were slightly lower than those treated with general anesthesia, both rates were in the 98% to 99% range. Furthermore, the single-center signals of shorter ICU stays and reduced hospital length of stay seen in prior analyses appear to be broadly and safely applicable to US TAVR centers as a whole. 6, 13, 14 These findings are even more notable because the current study evaluated the use of conscious sedation during its initial entry into US practice, and the outcomes for conscious sedation may improve as centers gain more experience. It should be noted that overall reductions in hospital length of stay in the current study, while statistically significant, were far more modest than those noted in prior single-center analyses of conscious sedation. This implies that reduction in hospital length of stay is influenced by more than just the anesthesia choice in the operating room, as has been noted by prior research regarding dedicated postprocedural TAVR care pathways. 12, 15 This may hold particular importance in the high-risk geriatric population treated with TAVR in our study, a group especially vulnerable to many ICU and hospital-related morbidities. 16, 17 The most important finding of this study is the observation that TAVR with conscious sedation can be performed safely. In addition, the current results suggest that conscious sedation may be associated with reduced rates of mortality. This finding contrasts with other international registry analyses that failed to detect a difference in these outcomes. 18, 19 The discrepancy between the US experience and prior smaller European experiences is likely multifactorial, but may reflect residual confounding attributable to unmeasured patient selection and center-related bias, variability in technique, evolving technologies, improving skill and facility with TAVR with conscious sedation over time, and greater statistical power in the current analysis. Given these possibilities, determining whether conscious sedation is Adjustments were made by inverse probability weighting. Relative risks were calculated for procedural duration and hospital length of stay using the Poisson model with robust variance. CI indicates confidence interval; and TAVR, transcatheter aortic valve replacement.
*Odds ratios report general anesthesia as the reference cohort for binary end points that were modeled using logistic regression. Adjustments were made by inverse probability weighting. CI indicates confidence interval; and PPM/ICD, permanent pacemaker/implantable cardiac defibrillator. *Odds ratios report general anesthesia as the reference cohort for binary end points that were modeled using logistic regression.
truly associated with reduced mortality cannot be definitively determined based on this analysis. What does appear consistent among this and prior studies is that conscious sedation can be safely and effectively used during TAVR. It is noteworthy that this study did report a crossover rate of 5.9% from conscious sedation to general anesthesia. Prior studies have suggested that vascular complications, hemodynamic compromise, and respiratory failure are the most common reasons for conversion. [20] [21] [22] Although the characteristics of the crossover group reported here suggest a trend toward worsening lung disease, additional studies will be needed to better characterize the risk factors for and predictors of conversion from conscious sedation to general anesthesia during TAVR.
One of the primary limitations of this study comparing conscious anesthesia with general anesthesia is possible confounding created by the simultaneous convergence of other technological and procedural advances in TAVR that might be differentially applied to patients treated with conscious sedation. We attempted to counterbalance these external factors, such as changes in valve design and sheath size, by examining only a brief period of time (16 months) in a selected group of patients (elective, percutaneous transfemoral cases) to ensure a period of relative technological and procedural stability.
We corrected for site effects and all factors associated with in-hospital TAVR mortality in an internally validated risk model. 10 Three separate falsification end points demonstrated effective correction for baseline differences between anesthesia type and outcomes, suggesting the model used in this analysis is robust. Despite this, there may have been residual selection bias at either the patient or institutional level that went unmeasured and cannot be fully quantified. The similarity in unadjusted baseline characteristics between the conscious sedation and general anesthesia groups suggests any possible effect is likely to be small, but it cannot be excluded.
Conscious sedation is a broad term that can apply to a wide variety of anesthesia/sedation techniques. These include isolated local anesthesia in which only superficial and subcutaneous agents are used, conscious sedation in which combinations of dexmedetomidine, propofol, benzodiazapenes, and narcotics are administered intravenously, and monitored anesthesia care in which these or other sedatives are administered by a trained anesthesia provider who actively manages sedation and is prepared to convert to general anesthesia when necessary. The analyzed data set did not contain enough detail to distinguish between these various forms of anesthesia intensity, precluding a more nuanced analysis of best anesthetic practices for TAVR. This lack of granularity also raises the possibility of measurement bias if different centers interpret the definition of conscious sedation (a depressed, but arousable state) and general anesthesia (a nonarousable state, but not explicitly requiring endotracheal intubation) in different fashions. This limitation is somewhat mitigated by random audits that are performed by the TVT Registry on a limited number of cases from each site annually. During these audits, patient charts are checked to confirm the validity of the coding of various patient and procedural characteristics to ensure quality of data. Beyond this, no specific analysis has been performed to assess the validity of the conscious sedation and general anesthesia codes specifically. Also of note, stroke is self-reported by site and not universally adjudicated by a neurologist, leading toward a bias toward underestimation of event rates, although we do not have reason to believe this would be differential between treatment groups. Despite these limitations, the current analysis will likely represent the best available evidence on the issue for the foreseeable future. Assuming the 30-day event rates observed in our analysis, a randomized trial powered for superiority evaluating this question would require 4776 patients.
A final potential limitation of this analysis is the unclear impact the use of conscious sedation may have had on provider use of transesophageal echocardiography. Although a number of sites in the United States and Europe use transesophageal echocardiography with conscious sedation-guided TAVR, 23 other reports suggest that transesophageal echocardiography is more commonly used in general anesthesia cases than conscious sedation cases. 16 Some have argued that the use of transesophageal echocardiography may allow for more optimal positioning and reduction in paravalvular leak during the procedure, which may result in longer-term morbidity and mortality benefits not seen in this study's 30-day follow-up period. 24 Unfortunately, the current registry does not contain core laboratoryadjudicated data on paravalvular leak, preventing any definitive comment on this possibility. Furthermore, it should be noted that any potential late improvement in survival would have to overcome the short-term benefits of conscious sedation seen in the current analysis.
In summary, this study supports the hypothesis that TAVR with conscious sedation is associated with superior clinical outcomes in comparison with TAVR with general anesthesia. Because the improved clinical outcomes come without significantly sacrificing procedural efficacy, these findings may have considerable impact on the TAVR procedure and care pathways going forward.
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